CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 258 filers reported holding CRISPR THERAPEUTICS AG in Q1 2020. The put-call ratio across all filers is 0.73 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2020 | $14,135,000 | -33.8% | 333,304 | -4.9% | 1.14% | -13.2% |
| Q4 2019 | $21,340,000 | +31.5% | 350,386 | +1.7% | 1.31% | +16.3% |
| Q3 2019 | $16,233,000 | -18.0% | 344,622 | -18.0% | 1.13% | +6.0% |
| Q2 2019 | $19,807,000 | +18.4% | 420,505 | -10.2% | 1.06% | +36.5% |
| Q1 2019 | $16,735,000 | +30.6% | 468,525 | +4.5% | 0.78% | +11.9% |
| Q4 2018 | $12,814,000 | -41.9% | 448,480 | -9.8% | 0.70% | -19.8% |
| Q3 2018 | $22,054,000 | +41.7% | 497,276 | +87.7% | 0.87% | +52.1% |
| Q2 2018 | $15,565,000 | -3.1% | 264,914 | -24.6% | 0.57% | +3.4% |
| Q1 2018 | $16,069,000 | +8.0% | 351,540 | -44.5% | 0.55% | +12.4% |
| Q4 2017 | $14,873,000 | +46.0% | 633,452 | +11.2% | 0.49% | +50.8% |
| Q3 2017 | $10,184,000 | – | 569,841 | – | 0.32% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 498,558 | $32,581,000 | 55.55% |
| NEA Management Company, LLC | 1,590,002 | $103,907,000 | 5.19% |
| ARK Investment Management | 8,237,122 | $538,296,000 | 3.75% |
| Nikko Asset Management Americas, Inc. | 4,262,736 | $277,078,000 | 3.54% |
| CLOUGH CAPITAL PARTNERS L P | 414,767 | $27,105,000 | 2.89% |
| Integral Health Asset Management, LLC | 220,000 | $14,377,000 | 2.79% |
| PLUSTICK MANAGEMENT LLC | 50,000 | $3,268,000 | 2.48% |
| HC Advisors, LLC | 53,944 | $3,525,000 | 2.43% |
| Green Alpha Advisors, LLC | 27,466 | $1,795,000 | 1.52% |
| EFG Asset Management (North America) Corp. | 84,356 | $5,516,000 | 1.28% |